Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Gynecologic 1

Conditions

Platinum-resistant Ovarian Cancer 1

Interventions

Paclitaxel 233 Carboplatin 217 Bevacizumab 139 Cisplatin 136 pembrolizumab 89 Gemcitabine 69 olaparib 54 Docetaxel 47 Topotecan 44 Radiotherapy 43 liposomal doxorubicin 41 Taxes 41 niraparib 38 Cyclophosphamide 36 Doxorubicin 30 Drug Therapy 29 Letrozole 28 Nivolumab 27 Magnetic Resonance Spectroscopy 25 Immunoglobulin G 25 Disulfides 24 Oxaliplatin 23 Albumin-Bound Paclitaxel 23 durvalumab 22 apatinib 21 Etoposide 21 Brachytherapy 21 lenvatinib 20 camrelizumab 20 Specimen Handling 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × afuresertib × Gynecologic × Clear all

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡